Latest News

Thursday, April 18, 2019

Blood Test for TBI Licensed for Use and Development on Abbot Laboratory Instruments

A Food and Drug Administration (FDA) approved blood test for mild traumatic brain injury (mTBI), also known as concussion, may become more widely available soon. The blood test (Banyan Brain Trauma In…

Read the full story

Wednesday, April 17, 2019

Research Agenda Created for Women Living with Parkinson's Disease

The Parkinson's Foundation Women and Parkinson’s Initiativeis the first patient-centered action agenda for improving quality of life for women with Parkinson's disease. The program …

Read the full story

Tuesday, April 16, 2019

Promising Results Published for Pembrolizumab to Treat Progressive Multifocal Leukoencephalopathy

As published in the New England Journal of Medicine, positive results have been seen in a small study of pembrolizumab (Keytruda; Merck, Kenilworth, NJ) for treatment of progressive multifocal le…

Read the full story

Tuesday, April 16, 2019

Free Resource for People Living With Migraine—Migraine Patient Guidelines

A new publication for people living with migraine, Migraine Patient Guidelines from The Global Healthy Living Foundation, is available for free download to assist people living with migraine…

Read the full story

Friday, April 12, 2019

First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer’s Disease

The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is being investigated for tre…

Read the full story

Thursday, April 11, 2019

Low Cholesterol May Increase Hemorrhagic Stroke Risk for Women

Results from a prospective cohort study published in Neurology show that women with low levels of low-density lipoprotein (LDL) cholesterol had increased risk of hemorrhagic stroke. Wom…

Read the full story

Thursday, April 11, 2019

FDA Warns About Unapproved Devices for Diagnosing and Treating Concussion

The Food and Drug Administration (FDA) has issued a warning regarding tools being marketed for assessing, diagnosing, or managing concussion that are not FDA-approved. The FDA notes that use of these …

Read the full story

Wednesday, April 10, 2019

Potential New Treatment for Photosensitive Epilepsy

Results of a phase 2a study (NCT02564029) published in Neurology show that CVL-865 (Cerevel Therapeutics, LLC, Boston, MA) has anticonvulsant activity in patients with photic epilepsy. …

Read the full story

Monday, April 08, 2019

Technology Has Potential to Halt Production of Mutated Protein in Huntington’s Disease and Spinocerebellar Ataxia

Early data supports a potential therapy for neurodegenerative diseases such as Huntington’s disease (HD) and spinocerebellar ataxia (SCA) that are caused by trinucleotide repeats.  The t…

Read the full story

Friday, April 05, 2019

New Drug Application Resubmitted for Istradefylline for Parkinson’s Disease OFF Periods

A new drug application has been resubmitted to the Food and Drug Administration (FDA) for istradefylline (KW-6002; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan). Istradefylline has been investigated as a…

Read the full story

Thursday, April 04, 2019

First Patients Dosed in Trial of Two-Drug Combination Therapy for Alzheimer’s Disease

The first patients were dosed in a Phase 2 clinical trial to assess AMX0035 (Amylyx Pharmaceuticals, Inc., Cambridge, MA) in patients with Alzheimer’s disease. AMX0035 is a two-drug combination …

Read the full story

Wednesday, April 03, 2019

Database of Eye-Tracking Movements Could Aid Diagnosis and Treatment

Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data points from 100,000 individ…

Read the full story

Tuesday, April 02, 2019

Clinical Trial Begins for Third-Generation CGRP-Antagonist Nasal Spray for Acute Migraine Treatment

The first patient has been enrolled in a phase 2/3, double-blind, placebo-controlled trial of intranasally administered BHV-3500 (Biohaven Pharmaceutical, New Haven, CT) being studied for acute treatm…

Read the full story

Monday, April 01, 2019

Biomarker Study Aims to Advance Understanding of ALS Diagnosis and Treatment

A clinical study starting in late 2019 will identify and measure biomarkers in patients with amyotrophic lateral sclerosis (ALS) and evaluate the treatment effect of edaravone (Radicava; Mitsubishi Ta…

Read the full story

Monday, April 01, 2019

FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MS

The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and active secondary progres…

Read the full story
Load More